BindingDB logo
myBDB logout

21 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27825552 152 Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.EBI Takeda Pharmaceutical Company Limited
26653735 81 Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.EBI Pfizer Inc.
26753813 22 Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.EBI University of Minnesota
25264600 64 Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.EBI Takeda Pharmaceutical Company Limited
25686153 73 Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.EBI University of Navarra
25192810 66 Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1 binding site.EBI Takeda Pharmaceutical Company Ltd
19715320 87 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI University of Florida
18061445 103 Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Research and Development
22175825 19 Potent inhibitors of LpxC for the treatment of Gram-negative infections.EBI Pfizer Inc.
22017539 75 Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.EBI Boehringer Ingelheim Pharmaceuticals Inc
18790648 317 Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.EBI University of Athens
18442906 40 Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.EBI North Dakota State University
17276676 112 A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16473009 23 Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
11585440 76 Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.EBI DuPont Pharmaceuticals Company
7932530 2 Heteroaryl-fused 2-phenylisothiazolone inhibitors of cartilage breakdown.EBI DuPont Merck Pharmaceutical Company
21524149 13 Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.BDB Suven Life Sciences Ltd
8632342 110 Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences.BDB Eli Lilly and Company
7651361 32 Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain.BDB Georgetown University